Lisa Wilson brings three decades of patent-related experience to KDB with pragmatic advice and service for life science and other clients from start-ups to large public companies. She brings a breadth of scientific knowledge and understanding for strategic worldwide patent portfolio development, patent prosecution, diligence and licensing of plant, pharmaceutical and biotechnical products.
Together with her PhD in molecular biophysics and biochemistry, Lisa’s in-house and law firm experience collectively create the foundation for her clear perspective on strategically managing intellectual property matters for KDB clients.
Her experience includes:
- Client counseling and worldwide patent portfolio management in diverse technologies including immunology, vaccines and antibodies, cancer therapeutics, gene therapy, viral-based products, molecular genetics, microbiology, small molecular pharmaceuticals, polymer chemistry, peptide therapeutics and diagnostics, and cancer stem cells and diagnostics
- Preparing or prosecuting a multitude of patent families in the pharmaceutical, chemical, biotech, medical device and plant industries
- Opinion work on infringement, validity and litigation issues and patent landscape analysis in the biotechnical, pharmaceutical, agricultural and food arts
- Due diligence representing clients in a range of life science investment deals, including a $25 million deal relating to implantable, combination drug delivery-device products with novel polymeric biomaterials
Prior to joining KDB, Lisa spent 14 years as a sole practitioner.
- Wilson, M.L. (2017) Presentation to the Plant Special Interest Group at AUTM 2017 Annual Meeting, Hollywood, FL. The U.S. Joins the International Treaty for Plant Genetic Resources for Food and Agriculture: Implications for Plant Technology Managers.
- Wilson, M.L. (2016) Panelist, 1st International Agrobiodiversity Congress, New Delhi, India. Working with USAID: How to Enhance the value of SeeD and like-minded initiatives.
- Wilson, M.L. (2005) American Conference Institute’s “The 5th Advanced Forum on Biotech Patents: Analysis, Insights and Strategies for new Challenges in Biotech Patents,” New York, NY. Enabling Biotech Patents: Is it Cold Fusion in Disguise?
- Tsvedos, E.J., Toffenetti, J.L and Wilson, M.L. (2000) Nat. Biotechnol. 18:795-796. Will Publication of Patent Applications Really Affect Biotechnology?
- Wilson IP Law, Principal, 2007 - 2021
- AAAS Science & Technology Felow, USAID, Bureau for Food Security, 2015 - 2017
- TyRx, Patent Counsel, 2007 - 2011
- Duane Morris, Partner, 2004 - 2006
- Hale & Dorr, Junior Partner, 2000 - 2004
- Kenyon & Kenyon, Associate, 1996 - 2000